WHIM Breast Cancer PDX Models
Inotiv is continuously growing a collection of highly characterized PDX models developed at Washington University and initially described in the article by Li et al. In the publication, it shows the Washington University Human in Mouse (WHIM) lines were mostly obtained from patients with advanced disease or larger primary tumors that rapidly developed lethal metastasis.
The group extensively characterized about 25 tumors in order to create a set in which genes and expression profiles can be used to determine the best way forward with treatment. Characterization was conducted at multiple stages from patient biopsy through PDX engraftment, propagation, and later passages.
Work with a highly characterized PDX breast cancer model
Many models already have accompanying WGS and or RNA-seq data and the bank of available characterization data is continuously growing.
Your research can also benefit from comprehensive patient history including stage at sample grafting, patient response to treatment, and ER, PR and Her2 status. For some models, quantitative proteomic profile, which includes signatures of PDXs resembling findings from breast cancer patients and the identification of overexpressed proteomic events not evident at the genomic level in both PDX and human samples. Other notable attributes include:
- Fulvestrant selective estrogen receptor degrader (SERD) resistance
- Estradiol responsiveness
Explore Our World-Class Collection PDX Models
Available as:
- Suspended PDX cells
- In-house in vivo efficacy studies
- In-house PK/PD studies
- Tumor Microarray
- FFPE slides
- Frozen chunks
